

PRODUCT INFORMATION



Ibrutinib

Item No. 16274

CAS Registry No.: 936563-96-1

Formal Name: 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one

Synonyms: Imbruvica, PCI 32765

MF: $C_{25}H_{24}N_6O_2$

FW: 440.5


Purity: $\geq 98\%$

UV/Vis.: λ_{max} : 260 nm

Supplied as: A crystalline solid

Storage: -20°C

Stability: ≥ 2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Ibrutinib is supplied as a crystalline solid. A stock solution may be made by dissolving the ibrutinib in the solvent of choice. Ibrutinib is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF), which should be purged with an inert gas. The solubility of ibrutinib in DMSO and DMF is approximately 30 mg/ml and approximately 0.25 mg/ml in ethanol.

Ibrutinib is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, Ibrutinib should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. Ibrutinib has a solubility of approximately 0.25 mg/ml in a 1:3 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Bruton's tyrosine kinase (BTK) is a member of the BTK/Tec family of protein tyrosine kinases involved in signal transduction pathways regulating proliferation, survival, migration, and tissue homing of B-cells.¹ Ibrutinib is an irreversible inhibitor of BTK ($IC_{50} = 0.5$ nM) that selectively blocks B cell activation, promoting apoptosis and preventing homing to the protective tumor microenvironment, at concentrations that do not affect T cell receptor signaling (1,000-fold more potent).^{2,3} It has been reported to inhibit autophosphorylation of BTK ($IC_{50} = 11$ nM), phosphorylation of PLC γ ($IC_{50} = 29$ nM), a substrate of BTK, and phosphorylation of ERK ($IC_{50} = 13$ nM), a further downstream kinase.² Its use has been examined clinically for the treatment of diseases associated with B cell antigen receptor signaling, including mantle cell lymphoma, chronic lymphocytic leukemia, and non-Hodgkin lymphoma.^{1,2,4}

References

1. Leslie, L.A. and Younes, A. *Leuk. Lymphoma* **54**(11), 2365-2376 (2013).
2. Honigberg, L.A., Smith, A.M., Sirisawad, M., et al. *Proc. Natl. Acad. Sci. USA* **107**(29), 13075-13080 (2010).
3. Herman, S.E.M., Gordon, A.L., Hertlein, E., et al. *Blood* **117**(23), 6287-6296 (2011).
4. Wu, M., Akinleye, A., and Zhu, X. *J. Hematol. Oncol.* **6**, 36 (2013).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/08/2017

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM